Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | DAO | P14920 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 4/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | CCR4 | P51679 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL224383 | 0.86 | HRH3 (0.40) | MAPTNPC1RAB9AMAOBMAOA | |
| SCHEMBL3834244 | 0.80 | MRGPRX4 (0.35) | MRGPRX4MAPTNPC1RAB9ATDP1 | |
| SCHEMBL221820 | 0.79 | LMNA (0.45) | MAPTTDP1POLBKMT2AMAOB | |
| SCHEMBL222298 | 0.77 | FFAR1 (0.43) | NPC1RAB9APOLBL3MBTL1MAOB | |
| SCHEMBL23457522 | 0.77 | MRGPRX4 (0.43) | MRGPRX4MAPTNPC1RAB9ATDP1 | |
| SCHEMBL29699442 | 0.77 | MRGPRX4 (0.43) | MRGPRX4MAPTNPC1RAB9ATDP1 | |
| SCHEMBL13359943 | 0.75 | NPC1 (0.47) | NPC1RAB9ATDP1ALDH1A1MAOB | |
| SCHEMBL13314745 | 0.74 | RXRA (0.43) | MRGPRX4MAPTNPC1RAB9APOLB | |
| SCHEMBL4427549 | 0.74 | KCNH2 (0.55) | MAPTNPC1RAB9ADAOMAOB | |
| SCHEMBL224611 | 0.72 | TP53 (0.45) | MAPTNPC1RAB9ATDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120004230-A1 | IMIDAZOLE DERIVATIVES | GALLEY GUIDO (DE) | 2012-01-05 | — | — | US | claimed |
| US-20100204233-A1 | IMIDAZOLE DERIVATIVES | GALLEY GUIDO | 2010-08-12 | — | — | US | claimed |
| US-20080146523-A1 | IMIDAZOLE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2008-06-19 | — | — | US | claimed |
| US-20220280527-A1 | TRACE AMINE ASSOCIATED RECEPTOR 1 AGONISTS AND PARTIAL AGONISTS FOR PAIN TREATMENT | PURDUE PHARMA L.P. (US) | 2022-09-08 | — | — | US | disclosed |
| US-20190201410-A1 | TRACE AMINE ASSOCIATED RECEPTOR 1 AGONISTS AND PARTIAL AGONISTS FOR PAIN TREATMENT | PURDUE PHARMA L.P. (US) | 2019-07-04 | — | — | US | disclosed |
| EP-3463359-A1 | TRACE AMINE ASSOCIATED RECEPTOR 1 AGONISTS AND PARTIAL AGONISTS FOR PAIN TREATMENT | Purdue Pharma LP (US) | 2019-04-10 | — | — | EP | disclosed |
| WO-2017210616-A1 | TRACE AMINE ASSOCIATED RECEPTOR 1 AGONISTS AND PARTIAL AGONISTS FOR PAIN TREATMENT | PURDUE PHARMA L.P. (US) | 2017-12-07 | — | — | WO | disclosed |
| US-8399463-B2 | Imidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2013-03-19 | — | — | US | disclosed |
| US-20120004230-A1 | IMIDAZOLE DERIVATIVES | GALLEY GUIDO (DE) | 2012-01-05 | — | — | US | disclosed |
| US-20100204233-A1 | IMIDAZOLE DERIVATIVES | GALLEY GUIDO | 2010-08-12 | — | — | US | disclosed |
| EP-2094668-A2 | 4-IMIDAZOLINES AS TAAR'S LIGANDS | F. Hoffmann-Roche AG (CH) | 2009-09-02 | — | — | EP | disclosed |
| WO-2008074679-A2 | 4-IMIDAZOLINES AS TAAR'S LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-06-26 | — | — | WO | disclosed |
| US-20080146523-A1 | IMIDAZOLE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190201410-A1 | TRACE AMINE ASSOCIATED RECEPTOR 1 AGONISTS AND PARTIAL AGONISTS FOR PAIN TREATMENT | TAAR1, TAAR5, OPRL1 | MRGPRX4 116/4885MAPT 649/4885NPC1 1764/4885 |
| US-20220280527-A1 | TRACE AMINE ASSOCIATED RECEPTOR 1 AGONISTS AND PARTIAL AGONISTS FOR PAIN TREATMENT | TAAR1, TAAR5, OPRL1 | MRGPRX4 109/4885MAPT 678/4885NPC1 1849/4885 |
| US-20100204233-A1 | IMIDAZOLE DERIVATIVES | TAAR1, TAAR5, TACR1 | MRGPRX4 93/4885MAPT 1256/4885NPC1 1248/4885 |
| US-20120004230-A1 | IMIDAZOLE DERIVATIVES | TAAR1, TAAR5, TACR1 | MRGPRX4 93/4885MAPT 1256/4885NPC1 1248/4885 |
| US-20080146523-A1 | IMIDAZOLE DERIVATIVES | TAAR1, TAAR5, TACR1 | MRGPRX4 93/4885MAPT 1256/4885NPC1 1248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.